FAQ about Qalsody (tofersen)

On 4/25/2023, the US Food and Drug Administration’s (FDA) announced that it approved Qalsody (tofersen) as a new treatment for SOD1 ALS.

As we celebrate this ground-breaking development in the fight against ALS, we want to thank everyone who worked tirelessly to make this monumental moment happen! While we still have a lot of work to find effective treatments and cures for everyone facing this devastating disease, this new treatment is a significant step toward our ultimate goal.

We know there are a lot of questions that people have in light of this exciting news. Here are answers to some of the frequently asked questions we are fielding from our ALS community.

Biogen is working on making Qalsody (tofersen) available as soon as possible. We encourage you to talk with your doctor and learn more on the website or contact Biogen at 1-877-725-7639. The Golden West Chapter will continue to provide updated information as it becomes available.

Our deepest gratitude to the entire ALS community for your advocacy efforts and to everyone living with ALS who participated in the clinical trials that led to this historic milestone.